Pharmacogenomics and sexuality: A vision

Climacteric

Volumn 16, Issue S1, 2013, Pages 25-30

  Nappi, R E ^a,b   Domoney, C ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Female sexual dysfunction; Pharmacogenomics; Sexual medicine

Indexed keywords

OSPEMIFENE; SEROTONIN 2A ANTAGONIST;

ARTICLE; CONTRACEPTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEREDITY; HORMONAL THERAPY; HUMAN; MEDICAL PRACTICE; MENARCHE; MENOPAUSE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SEXUALITY; VAGINA ATROPHY;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PHARMACOGENETICS; REPRODUCTIVE HEALTH; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84880276631     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.806402     Document Type: Article

References (74)

1. Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010 ; 7 : 314-26
2. McCabe M, Althof SE, Assalian P, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2010 ; 7 : 327-36
3. Burri AV, Cherkas LM, Spector TD. The genetics and epidemiology of female sexual dysfunction (FSD): A review. J Sex Med 2009 ; 6 : 646-57
4. Basson R. Recent advances in women's sexual function and dysfunction. Menopause 2004 ; 11 : 714-25
5. Nappi R E. N ew attitudes to sexuality in the menopause: Clinical evaluation and diagnosis. Climacteric 2007 ; 10(Suppl 2) : 105-8 (Pubitemid 47450847)
6. Nappi R, Salonia A, Traish A M, et a l. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med 2005 ; 2 : 4-25 (Pubitemid 40468189)
7. Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007 ; 369 : 409-24 (Pubitemid 46177229)
8. Basson R, Rees P, Wang R, Montejo A L, Incrocci L. S exual function in chronic illness. J Sex Med 2010 ; 7 : 374-88
9. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: A systematic review and metaanalysis. J Sex Med 2012 ; 9 : 1497-507
10. Fooladi E, Bell RJ, Davis SR. Management strategies in SSRIassociated sexual dysfunction in women at midlife. Climacteric 2012 ; 15 : 306-16
11. Wierman M E, Nappi R E, Avis N, et a l. E ndocrine aspects of women's sexual function. J Sex Med 2010 ; 7 : 561-85
12. N appi RE, Polatti F. The use of estrogen therapy in women's sexual functioning. J Sex Med 2009 ; 6 : 603-16
13. Spector IP, Carey MP. Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Arch Sex Behav 1990 ; 19 : 389-408 (Pubitemid 20233246)
14. Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual diffi culty and dysfunction? J Sex Med 2006 ; 3 : 589-95
15. Laumann EO, Paik A, Sexual Rosen RC. Dysfunction in the United States. Prevalence and predictors. JAMA 1999 ; 281 : 537-44 (Pubitemid 29081307)
16. Nicolosi A, Laumann EO, Glasser DB, et al. Sexual behavior and sexual dysfunctions after age 40: The Global Study of Sexual Attitudes and Behaviors. Urology 2004 ; 64 : 991-7 (Pubitemid 39469520)
17. Shifren J L, Monz B U, Russo P A, Segreti A, Johannes C B. S exual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008 ; 112 : 970-8
18. Nappi R E, Lachowsky M. M enopause and sexuality: Prevalence of symptoms and impact on quality of life. Maturitas 2009 ; 63 : 138-41
19. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008 ; 14 : 1441-9 (Pubitemid 352008425)
20. .Leiblum SR, Koochaki P E, Rodenberg G A, Barton I P, Rosen R C. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006 ; 13 : 46-56
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000
22. Basson R, Leiblum S, Brotto L, et al. Revised defi nitions of women's sexual dysfunction. J Sex Med 2004 ; 1 : 24-39
23. Bancroft J. T he medicalization of female sexual dysfunction: The need for caution. Arch Sex Behav 2002 ; 3 : 451-5 (Pubitemid 38471090)
24. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J Sex Med 2010 ; 7 : 586-614
25. Bachmann G A, Leiblum S R, Grill J. B rief sexual inquiry in gynecologic practice. Obstet Gynecol 1989 ; 73 : 425-7 (Pubitemid 19063625)
26. Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don't talk about when we don't talk about sex: Results of a national survey of US obstetrician/gynecologists. J Sex Med 2012 ; 9 : 1285-94
27. P faff DW. Brain Arousal and Information Theory: Neural and Genetic Mechanisms. Cambridge, Mass: Harvard University Press, 2006
28. Pfaff D, Frohlich J, Morgan M. Hormonal and genetic infl uences on arousal-sexual and otherwise. Trends Neurosci 2002 ; 25 : 45-50 (Pubitemid 34093785)
29. Majdic G, Tobet S. Cooperation of sex chromosomal genes and endocrine infl uences for hypothalamic sexual differentiation. Front Neuroendocrinol 2011 ; 32 : 137-45
30. Schober JM, Pfaff D. T he neurophysiology of sexual arousal. Best Pract Res Clin Endocrinol Metab 2007 ; 21 : 445-61 (Pubitemid 47387102)
31. McDevitt M A, Glidewell-Kenney C, Jimenez M A, et a l. N ew insights into the classical and non-classical actions of estrogen: Evidence from estrogen receptor knock-out and knock-in mice. Mol Cell Endocrinol 2008 ; 290 : 24-30
32. Traish A M, Botchevar E, Kim N N. B iochemical factors modulating female genital sexual arousal physiology. J Sex Med 2010 ; 7 : 2925-46
33. Burri A. B ringing sex research into the 21st century: Genetic and epigenetic approaches on female sexual function. J Sex Res 2013 ; 50 : 318-28
34. Burnett AL, Goldstein I, Andersson KE, et al. Future sexual medicine physiological treatment targets. J Sex Med 2010 ; 7 : 3269-304
35. Burri, A, Cherkas, L, Spector T. The genetic epidemiology of female sexual dysfunction: A review. J Sex Med 2009 ; 6 : 646-57
36. Witting K, Santilla P, Rijsdijk F, et al. Correlated genetic and non-shared environmental infl uences account for the comorbidity between female sexual dysfunctions. Psychol Med 2009 ; 26 : 1-13
37. Dawood K, Kirk K M, Bailey J M, Andrews P W, Martin N G. Genetic and environmental infl uences of the frequency of orgasm in women. Twin Res Hum Genet 2005 ; 8 : 27-33 (Pubitemid 40478168)
38. Dunn KM, Cherkas LF, Spector TD. Genetics of variation in female orgasmic function; a twin study. Biol Lett 2005 ; 22 : 260-3 (Pubitemid 41374878)
39. Hettema JM, Neale MC, Kendler KS. A review and metaanalysis of the genetic epidemiology of anxiety disorders. Am J Psychiatr 2001 ; 158 : 1568-15
40. Sullivan P F, Neale M C, Kendler K S. G enetic epidemiology of major depression: Review and meta-Analysis. Am J Psychiatr 2000 ; 157 : 1552-15
41. Jang K, Wesley W J, Vemon P A. Heritability of the big fi ve personality dimensions and their facets: A twin study. J Pers 1996 ; 64 : 577-591 (Pubitemid 126443604)
42. Burri A, Greven C, Leupin M, Spector T, Rahman Q. A multivariate twin study of female sexual dysfunction. J Sex Med 2012 ; 9 : 2671-81
43. Clayton AH, Groth J. Etiology of female sexual dysfunction. Womens Health 2013 ; 9 : 135-7
44. Burri A, Rahman Q, Spector T. Genetic and environmental risk factors for sexual distress and its association with female sexual dysfunction. Psychol Med 2011 ; 41 : 2435-45
45. Burri A, Spector T, Rahman Q. T he etiological relationship between anxiety sensitivity, sexual distress, and female sexual dysfunction is partly genetically moderated. J Sex Med 2012 ; 9 : 1887-96
46. Pfaus J G. P athways of sexual desire. J Sex Med 2 009; 6 : 1506-33
47. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-Associated sexual side-effects. Neuropsychopharmacology 2006 ; 31 : 2281-8 (Pubitemid 44413208)
48. Perlis R H, Laje G, Smoller J W, Fava M, Rush A J, McMahon F J. Genetic and clinical predictors of sexual dysfunction in citalopramtreated depressed patients. Neuropsychopharmacology 2009 ; 34 : 1819-28
49. Ben Zion I Z, Tessler R, Cohen L, et a l. P olymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: Desire, arousal and sexual function. Mol Psychiatry 2006 ; 11 : 782-6 (Pubitemid 44141811)
50. Stahl SM, Sommer B, Allers KA. M ultifunctional pharmacology of fl ibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011 ; 8 : 15-27
51. Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB. Heritability of responses to painful stimuli in women: A classical twin study. Brain 2007 ; 13 : 27-42
52. Giraldi A, Marson L, Nappi R, et al. Physiology of female sexual function: Animal models. J Sex Med 2004 ; 1 : 237-53 (Pubitemid 40424633)
53. Salonia A, Giraldi A, Chivers ML, et al. Physiology of women's sexual function: Basic knowledge and new fi ndings. J Sex Med 2010 ; 7 : 2637-60
54. Abdel-Hamid I A, Andersson K E. P harmacogenetics and pharmacogenomics of sexual dysfunction: Current status, gaps and potential applications. Pharmacogenomics 2009 ; 10 : 1625-44
55. Gerber S, Bongiovanni A M, Ledger W J, Witkin S S. I nterleukin-1beta gene polymorphism in women with vulvar vestibulitis syndrome. Eur J Obstet Gynecol Reprod Biol 2003 ; 107 : 74-7 (Pubitemid 36194760)
56. Jeremias J, Ledger WJ, Witki SS. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. Am J Obstet Gynecol 2000 ; 182 : 283-5 (Pubitemid 30127336)
57. Burri A, Hysi P, Clop A, Rahman Q, Spector TD. A genome-wide association study of female sexual dysfunction. PLoS One 2012; 7 : E35041
58. Kalow W. Pharmacogenetics and pharmacogenomics: Origin, status, and the hope for personalized medicine. Pharmacogenomics J 2006 ; 6 : 162-5 (Pubitemid 43811566)
59. Shastry B S. G enetic diversity and new therapeutic concepts. J Hum Genet 2005 ; 50 : 321-8 (Pubitemid 41206923)
60. Elaut E, Buysse A, De Sutter P, et a l. R elation of androgen receptor sensitivity and mood to sexual desire in hormonal contraception users. Contraception 2012 ; 85 : 470-9
61. Visvanathan K, Gallicchio L, Schilling C, et a l. C ytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol 2005 ; 106 : 1372-81 (Pubitemid 41668959)
62. Massart F. Human races and pharmacogenomics of effective bone treatments. Gynecol Endocrinol 2005 ; 20 : 36-44 (Pubitemid 40445239)
63. Rebbeck TR, Troxel AB, Norman S, et al. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 2007 ; 166 : 1392-9 (Pubitemid 350209049)
64. Cooke GE. Post-menopausal hormone therapy and cardiovascular events: A new paradigm based on pharmacogenetics? Future Cardiol 2008 ; 4 : 19-21
65. Yu KD, Huang AJ, Shao ZM. Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: A CYP2D6 multiplegenotype-based modeling analysis and validation. PLoS One 2010; 5 : E15649
66. Justenhoven C, Obazee O, Brauch H. The pharmacogenomics of sex hormone metabolism: Breast cancer risk in menopausal hormone therapy. Pharmacogenomics 2012 ; 13 : 659-75
67. Notelovitz M. Clinical opinion: The biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. Med Gen Med 2006; 8 : 85
68. Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 2004 ; 5 : 57-65 (Pubitemid 38088480)
69. Herrington D M, Howard TD. ER-Alpha variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics 2003 ; 4 : 269-77 (Pubitemid 36546608)
70. Kobayashi N, Fujino T, Shirogane T, et a l. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 2002 ; 4 : 193-201 (Pubitemid 34211974)
71. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefi ts associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007 ; 4 : 1001-8 (Pubitemid 47079633)
72. Fooladi E, Bell RJ, Davis SR. Management strategies in SSRIassociated sexual dysfunction in women at midlife. Climacteric 2012 ; 15 : 306-16
73. Portman D J, Bachmann G A, Simon J A ; a nd the Ospemifene Study Group. Ospemifene, anovel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013 Jan 28. Epub ahead of print
74. Zhang X, Allan G F, Tannenbaum P, et a l. P harmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator. J Steroid Biochem Mol Biol 2013 ; 134 : 51-8